1 **Phase 1 Safety and Pharmacokinetics Studies of BRII-196 and BRII-198,**
2 **SARS-CoV-2 Spike-Targeting Monoclonal Antibodies**
3

4 Yao Zhang^{1,3,¶}, Xiaohua Hao^{2, ¶}, Ji Ma³, Mingming Wang³, Yanyan Li³, Yang Liu³,
5 Dong Zhao², Wen Zhang², Chunming Li³, Li Yan³, Qing Zhu^{1,3,*}, Fujie Zhang^{2,*}
6

7 ¹ TSB Therapeutics, Beijing, China

8 ² Beijing Ditan Hospital, Capital Medical University, Beijing, China

9 ³ Brii Biosciences Inc., Durham, NC, US

10
11 *: Corresponding authors:

12 Qing Zhu

13 Email address: qing.zhu@briibio.com

14 Fujie Zhang

15 Email address: treatment@chinaaids.cn
16

17 [¶]These authors contributed equally to this work.

18 **Running title:** Safety and PK of COVID-19 mAbs in human

19 **Keywords.** SARS-CoV-2; monoclonal antibody therapy; BRII-196; BRII-198

20 **Clinical Trials Registration.** NCT04479631 and NCT04479644

21 **Funding:** These studies were sponsored by TSB Therapeutics.

22 **Abstract**

23 **Background.** BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal
24 neutralizing antibodies with modified Fc region that extends half-life and are being
25 developed as cocktail therapy for the treatment of COVID-19. Safety, tolerability,
26 pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 were investigated
27 in healthy adults.

28 **Methods.** Single ascending doses of BRII-196 and BRII-198 were evaluated in
29 parallel in the first-in-human, placebo-controlled phase 1 studies. A total of 32 healthy
30 adults were randomized and received a single intravenous infusion of 750, 1500, and
31 3000 mg of BRII-196 (n=12), BRII-198 (n=12), or placebo (n=8) and were followed
32 for 180 days.

33 **Results.** All infusions were well tolerated at infusion rates between 0.5 mL/min to 4
34 mL/min with no dose-limiting adverse events, deaths, serious adverse events, or any
35 systemic or local infusion reactions. Most treatment-emergent adverse events were
36 isolated asymptomatic laboratory abnormalities of Grade 1-2 in severity. Each mAb
37 displayed pharmacokinetics expected of Fc-engineered human IgG1 with mean
38 terminal half-lives of approximately 46 days and 76 days, respectively, with no
39 evidence of significant anti-drug antibody development.

40 **Conclusions.** BRII-196 and BRII-198 were well-tolerated. Clinical results support
41 further development as therapeutic or prophylactic options for SARS-CoV-2
42 infection.

43 **Background**

44 As of March 2021, globally, over 120 million people have been infected by
45 SARS-CoV-2, resulting in more than 2.6 million death by Coronavirus Disease 2019
46 (COVID-19). The number of cases continues to rise[1].

47 The development of safe and effective therapeutics represents a key strategy to curb
48 COVID-19 mortality and morbidity. Several approved medications (e.g., chloroquine,
49 hydroxychloroquine, lopinavir/ritonavir) have been "repurposed" and evaluated, none
50 of which have been shown associated with improved clinical outcomes[2, 3]. There
51 have been limited treatment options, including remdesivir, dexamethasone, and
52 convalescent plasma, that demonstrated clinical efficacy in subsets of patients with
53 COVID-19[4-7].

54 Neutralizing monoclonal antibodies (mAbs) represent a promising therapeutic option
55 in preventing and treating known and emerging infectious diseases, including
56 viruses[8]. Recent clinical trials of mAbs reported positive results indicating
57 virological and clinical benefits among outpatients with COVID-19 [9, 10]. In addition,
58 several COVID-19 vaccines offering>90% protection have become available for
59 emergency use [11, 12]. However, recent data showed that several mutations identified
60 in the receptor binding domain (RBD) of spike protein in the emerging new variants
61 conferred reduced activity to neutralization by the antibodies that were developed as a
62 therapy for treatment or elicited by vaccines for prevention [13, 14]. These emergent
63 variants present new challenges for mAb therapy and threaten the protective efficacy
64 of current vaccines and mAbs. Therefore, additional mAb treatment options,
65 especially a cocktail of antibodies targeting distinct epitopes, are needed as a critical
66 strategy to reduce the generation and selection of resistant viruses during treatment

and ensures binding and neutralization of the antibodies to new variants.

BRII-196 and BRII-198, two recombinant human IgG1 mAbs that target the distinct epitope regions in RBD in coronavirus spike glycoproteins non-competitively, are under clinical development as a cocktail for the treatment of COVID-19 in outpatients.

BRII-196 and BRII-198 are derived directly from human B cells of patients who recovered from COVID-19 [15] with effective neutralizing activity against not only the original isolate of SARS-CoV-2 but also the new variants of concerns, including B.1.351 (as known South African variant) and P1 from Brazil [16, 17]. BRII-196 and BRII-198 are engineered with a triple-amino-acid (M252Y/S254T/T256E [YTE]) substitution in the fragment crystallizable (Fc) region to allow an extended half-life [18, 19] and reduced Fcγ receptor binding for potential risk of Fc-mediated antibody dependent enhancement (ADE) (unpublished data).

The back-to-back first-in-human phase 1 studies in healthy adult participants were designed and conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of BRII-196 and BRII-198 individually before initiating clinical studies of BRII-196 and BRII-198 in combination in patients.

Methods

Study design and participants

BRII-196-001 and BRII-198-001 are two first-in-human phase 1, randomized, single-blind, placebo-controlled, single ascending dose escalation studies in which BRII-196 and BRII-198 were evaluated respectively among healthy adults. These studies were conducted at a single phase 1 unit in China from July 2020 to February

2021 (registered at ClinicalTrials.gov under registration number NCT04479631 and
NCT04479644). The study protocol, amendments, and informed-consent forms were
reviewed and approved by the Institutional Ethics Committee (IEC). The IEC
included Guo'an Wu, Wangyan Jia, Xiulan Li, Xiangmei Zhao, Zhiyun Yang,
Xingwang Li, Xianbo Wang, Hanqiu Zhan, Hui Zeng, Yajie Wang, Yun'ao Zhou, and
Gang Wan from Beijing Ditan Hospital, Capital Medical University; Kairong Wang
and Yangang Tian from Beijing Lvli Law Firm; and Jianguo Sun as a community
representative. The study was conducted in accordance with the International
Conference on Harmonisation Guidance for Good Clinical Practice guidelines and all
applicable local regulatory requirements and laws. Participants provided written
informed consent before any study-related procedures were performed.

Inclusion and exclusion criteria for the two studies were identical. Eligible
participants were healthy male or female adults aged 18 to 49 years, had a body
weight ≤ 100 kg and a body mass index of 18-24 kg/m², and were in good health
determined by no clinically significant findings from medical history, physical
examination including vital signs, electrocardiogram (ECG), and clinical laboratory
assessments. Women were not pregnant or lactating. Exclusion criteria included a
history of SARS-CoV-2 infection or exposure, a history of severe allergic reactions,
use of any medications that were started within 14 days before randomization, a
positive test for human immunodeficiency virus (HIV) or hepatitis B virus or hepatitis
C virus, a history of drug or alcohol abuse within 1 year before the screening, or any
history of a medical or psychiatric condition that would place them at risk or interfere
with study participation. Participants were also excluded if they were unwilling to use

112 necessary contraception during the study. A complete list of exclusion criteria is
113 included in [Supplementary Material 1](#).

114 **Study Procedures**

115 Three dose-level cohorts (750, 1500, and 3000 mg) were included to evaluate each
116 mAb and were initiated in a dose-escalation design. In each cohort, participants were
117 randomized at a 3:1 ratio to receive either the single mAb (n=3 or 6) or placebo (n=1
118 or 2). mAbs or placebo was dispensed into normal saline and was administered via
119 intravenous infusion on Day 1. The infusion started at the initial rate of 0.5 mL/min,
120 gradually increasing to a maximum rate of 4 mL/min. The participants were masked
121 to the treatment assignment and were admitted to the phase 1 unit for monitoring for 7
122 days post-dosing. The first participant in each cohort who received mAb infusion was
123 monitored for 24 hours before administering study intervention to the subsequent
124 participants. A Safety Review Committee made Dose-escalation recommendations
125 upon review of predefined safety data.

126 Vital signs, physical examinations, safety laboratory tests including hematology and
127 chemistry, and ECG were obtained before and after study drug administration on days
128 2, 4, 6, 8, 15, 22, 31, 61, 91, 121, 151, and at the end of the study on day 181. All
129 adverse events (AEs), including infusion reactions and serious adverse events (SAEs)
130 occurring throughout the trial, were recorded and assessed by study physicians at the
131 site. AEs were coded with the Medical Dictionary for Regulatory Activities
132 (MedDRA) version 23.1, and severity was graded using the Common Terminology
133 Criteria for Adverse Events (CTCAE) version 5.0, November 27, 2017.

134 **Pharmacokinetics and Immunogenicity Assessments**

135 The pharmacokinetics parameters were evaluated using blood samples collected
136 before dosing, at 3 and 8 hours post dose, and days 2, 4, 6, 8, 15, 22, 31, 61, 91, 121,
137 151, and 181. BRII-196 or BRII-198 serum concentrations were measured using
138 validated enzyme linked immunosorbent assays (ELISA) with the lower limit of
139 quantitation (LLOQ) at 150 ng/mL. Serum samples for anti-drug antibody (ADA)
140 assays were collected at the following time points: pre-dose on day 1 and at days 15,
141 31, and 181. Two validated titer-based 3-stage ELISA assays were used to detect
142 presences of ADAs from subjects over the study durations.

143 **Study Outcomes**

144 Primary endpoints were incidence of adverse events (AEs) and change from pre-dose
145 baseline in clinical assessments, including vital signs, ECG readings, and laboratory
146 results. Secondary endpoints included the pharmacokinetics profiles and presence of
147 ADAs to BRII-196/BRII-198 in samples collected after dosing for up to 180 days.

148 **Statistical Analysis**

149 The sample size of each study was consistent with a phase 1 first-in-human study. The
150 safety analysis included all participants who were randomized and received any dose
151 of the study drug. Categorical and continuous data were summarized descriptively.
152 Participants were analyzed according to the study drug they received. Participants
153 receiving placebo in different cohorts of each study were pooled in the analysis.

154 The PK parameters were estimated by non-compartmental analyses using WinNonlin
155 module in the Phoenix Platform (version 8.3.1.5014, Certara Inc., Princeton, NJ
156 08540). Calculations were performed prior to rounding, and nominal sampling times
157 were used in the pharmacokinetic analysis. All pharmacokinetic parameters and

summary statistics are reported to 3 significant digits except for $T_{\max}$ (reported in median values), which is reported to 1 decimal place.

Data Availability:

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Results

From July 12, 2020, to August 10, 2020, a total of 135 participants were screened, with 16 and 17 eligible and enrolled for BRII-196-001 and BRII-198-001 studies, respectively (**Figure 1**). The demographics of the study population are summarized in **Table 1**, consisting of 28 (84.8%) men and 5 women with a median age of 33.0 years and a median BMI of 21.9 kg/m².

A total of 12 participants received a single dose of BRII-196 IV infusion, 12 participants received a single dose of BRII-198 IV infusion, and 8 participants received placebo (normal saline). One participant randomized in BRII-198-001 study did not receive the infusion because of elevated blood pressure before dosing. All participants received their full planned dose except for 3 participants assigned to 750 mg of BRII-196 and 1 participant assigned to placebo for whom the received volume was approximately 10% less than the intended volume due to the remaining volume left within the infusion set. All participants dosed have completed study visits. Total infusion duration for BRII-196 or BRII-198 at investigated dose levels were 1.53-1.70 hours (750 mg), 2.27-2.43 hours (1500 mg), and 3.58-3.75 hours (3000 mg) ([Supplementary Table 1](#)).

181 **Safety**

182 BRII-196 and BRII-198 administration was safe and well-tolerated. No deaths,
 183 serious AEs, treatment-emergent adverse events (TEAEs) leading to early termination,
 184 or infusion-related reactions occurred during the study. Adverse events reported in
 185 BRII-196-001 and BRII-198-001 are summarized in **Table 2** and **Table 3**, respectively.
 186 26 (81%) participants had at least one treatment-emergent adverse events, including
 187 18 (75%) participants receiving BRII-196 or BRII-198 compared to 8 (100%)
 188 participants receiving placebo. Overall incidences of adverse events were balanced
 189 between groups receiving BRII-196 or BRII-198 and placebo. The most common
 190 TEAEs were isolated asymptomatic laboratory abnormalities of CTCAE Grade 1 or 2
 191 in severity that did not require medical intervention and typically normalized or
 192 returned to baseline level within four weeks ([Supplementary Table 2](#)). Seven out of 24
 193 participants had 8 Grade 1 or 2 adverse events that were considered by the
 194 investigators as related to BRII-196 or BRII-198, including increased blood total
 195 bilirubin, increased alanine aminotransferase, decreased neutrophil count, and
 196 decreased white blood cell count ([Supplementary Table 3](#)). No safety issues were seen
 197 with respect to vital signs or ECG measurements. No dose-dependent pattern of any
 198 adverse events was observed.

199 **Pharmacokinetics**

200 Pharmacokinetic data were available for a total of 12 participants each for BRII-196
 201 and BRII-198 over the 181-day study duration. Following a single intravenous
 202 infusion of BRII-196 or BRII-198 at 750, 1500, and 3000 mg, mean serum PK
 203 parameters, including C_{max} and AUC, increased in an approximately
 204 dose-proportional manner (**Table 4, Figure 2**). The mean systemic serum clearances
 205 were 75.4 and 57.0 mL/day for BRII-196 and BRII-198, respectively. The mean
 206 terminal half-lives ($t_{1/2}$) of BRII-196 and BRII-198 were 44.6-48.6 days and 72.2-83.0
 207 days. The relatively shorter terminal half-life of BRII-196 correlated with slightly
 208 higher systemic clearance.

209 **ADA Response**

210 In BRII-196-001 study, a total of 4 out of 12 participants had positive ADA samples in
 211 the screening assay, but all tested negative in the follow-up confirmatory assay. In
 212 BRII-198-001 study, one participant who received BRII-198 had positive ADA
 213 samples in the screening assay but later confirmed negative in the tier-2 confirmatory
 214 assay.

215 **Discussion**

216 BRII-196 and BRII-198 are fully human mAbs that bind to noncompeting epitope
 217 regions on the RBD of SARS-CoV-2 S glycoprotein that interacts with the
 218 angiotensin-converting enzyme 2 (ACE2) to enter human cells [20]. Therefore, they
 219 neutralize virus infection by preventing virus binding to ACE2, blocking virus entry
 220 and subsequent virus infection as demonstrated in vitro and in vivo [15, 21]. The
 221 combined use of 2 independently neutralizing antibodies is likely to reduce the risk of

222 treatment failure from the development of virus escape mutants or new variants that
 223 may arise during an outbreak. Currently approved COVID -19 vaccines were
 224 constructed against the original virus, of which attenuation of serum neutralization
 225 activity has been observed[14, 22]. In a recent trial conducted in South Africa, the
 226 ChAdOx1 nCoV-19 vaccine did not protect against mild-to-moderate COVID-19 due
 227 to the B.1.351 variant [23]. Pseudo viruses harboring mutations found in B.1.351
 228 South Africa origin, P.1 Brazil origin, B.1.526 New York origin, L452R, and the spike
 229 protein from the California origin variant lineage B.1.427/B.1.429, had significantly
 230 reduced susceptibility to bamlanivimab [24], a mAb authorized for emergency use. In
 231 addition, its approved cocktail with etesevimab under EUA was also tested inactive
 232 against the live virus of B.1.351 South Africa [17]. As some of these variants are
 233 beginning to spread around the world, it has posed a real threat to vaccine and
 234 antibody therapies. By contrast, BR11-196 and BR11-198 cocktail retained their
 235 neutralizing activity against all variants tested, including B1.1.7 UK variant, B1.357
 236 South Africa variant, and P1 Brazilian variants[16, 17], thereby could provide more
 237 treatment options to patients.

238 In these first-in-human clinical studies, intravenous administration of BR11-196 and
 239 BR11-198 were both safe and well-tolerated in healthy adult participants receiving a
 240 single dose up to 3000 mg, with no infusion reactions or AEs leading to adjustment or
 241 discontinuation of the infusion. Study participants were followed up to 180 days
 242 post-dosing considering the expected prolonged half-lives of the mAbs. Except for
 243 one SAE, one Grade 4 elevation of creatine phosphokinase, and one Grade 3 elevation
 244 of triglycerides, all deemed as not related to study drugs, all AEs reported were Grade
 245 1-2 in severity, with the majority being isolated asymptomatic transient laboratory
 246 abnormalities. There were no safety concerns regarding vital signs or ECGs. The

247 safety observations in these phase 1 studies are consistent with the expected safety
248 profile of human IgG1 mAbs in healthy subjects with no endogenous target.

249 With YTE modification, both BRII-196 and BRII-198 demonstrated anticipated 2-3
250 folds half-life extension in healthy adult subjects. In comparison with BRII-198, the
251 relatively shorter half-life observed with BRII-196 correlates with slightly higher
252 systemic clearance. As both antibodies showed comparable increased binding
253 affinities to human and cynomolgus monkey FcRns at pH 6.0 in vitro (unpublished
254 data), different molecular properties such as charge variants, glycan profiles, and
255 overall thermal stability might contribute to the observed differences. With up to a
256 3-week optimal treatment window for neutralizing antibodies for COVID-19 patients,
257 both antibodies are expected to provide comparable target coverage at the same dose
258 level.

259 BRII-196 and BRII-198 have several advantages that may facilitate their use for the
260 treatment and prevention of SARS-COV-2 infections. First, mAbs targeting specific
261 viral epitopes, including BRII-196 and BRII-198, belong to a platform technology
262 associated with a favorable safety profile. Findings regarding safety and tolerability in
263 phase 1 trials of BRII-196 and BRII-198 are consistent with the expectation, which
264 support an expedited development towards approval for future clinical use. Second,
265 targeting distinct viral epitopes in the RBD of SARS-COV-2 spike protein
266 non-competitively, BRII-196 and BRII-198 can be used in combination to provide
267 additive antiviral effect, reduce the generation of resistant viruses to treatment, and
268 retain activity against emergent naturally occurring variants as mentioned above.

269 Third, BRII-196 and BRII-198 are engineered with YTE substitution in the Fc region
270 to allow an extended half-life, demonstrated in the pharmacokinetic findings from

271 both phase 1 studies, with which BRII-196 and BRII-198 can potentially maintain an
272 adequate drug coverage over an extended period of time and subsequently are better
273 positioned for prophylactic use. Lastly, while YTE improves the half-life of the
274 antibody, it also reduced binding activity of BRII-196 and BRII-198 against human
275 Fcγ receptors, thereby minimizing the potential risk of Fc-mediated antibody
276 dependent enhancement of diseases.

277 In summary, BRII-196 and BRII-198 were generally safe and well-tolerated in healthy
278 adult participants. Pharmacokinetic and immunogenicity assessments demonstrated
279 linear pharmacokinetics with prolonged half-lives and no ADA development up to
280 180 days after a single dose. These findings support further development of BRII-196
281 and BRII-198 for the treatment and prophylaxis of SARS-COV-2 infection in the
282 pandemic outbreak. BRII-196 and BRII-198 combination is currently under
283 development in ACTIV-2, a platform phase 2/3 clinical study, for treatment of
284 COVID-19 in outpatients [25].

285 **Acknowledgment:** The authors thank all the study participants in these clinical
286 studies, without whom the studies would not have been possible. We thank Dr Yibo
287 Zhou, Jianmin Jing, and Yonghong Mang, for their contributions in the studies. We
288 also thank D.Margolis for critically reviewing the manuscript and Dr. Chan Gao for
289 her assistance with formatting/editing and submission.

290 **Financial support:** These trials were sponsored by TSB Therapeutics, a subsidiary
291 company of Brie Biosciences. Y.Z., J.M., Y.L., Y.Y.L., M.W., C.L., L.Y., and Q.Z. are
292 employees of Brie Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics.
293 F.J.Z. received support from TSB for participation as a principal investigator in the
294 study.

295 **Author contributions:** Brie Biosciences was involved in the study design, collection,
296 analysis and interpretation of data, the writing of this report, and the decision to
297 submit this manuscript for publication. F.J.Z., X.H.H, D.Z., and W.Z. reviewed
298 protocol, and were responsible for study implementation and data collection at the
299 study site. All authors at Brie Biosciences had access to all study data for review,
300 participated in interpretation of the data and in drafting and revising the article for
301 important intellectual content, and provided final approval of the submitted
302 manuscript. All authors assume responsibility for the integrity and completeness of
303 the reported data. Y.Z., J.M., Y.L., and Q.Z prepared the manuscript.

304 **Potential conflicts of interest.** Y.Z., J.M., Y.L., Y.L., M.W., C.L., L.Y., and Q.Z. are
305 employees of Brie Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics. All
306 other authors report no potential conflicts. All authors have submitted the ICMJE
307 Form for Disclosure of Potential Conflicts of Interest.

308 **References**

- 309 1. Johns_Hopkins_Coronavirus_Resource_Center. COVID-19 Map. Available at:
310 <https://coronavirus.jhu.edu/map.html>. Accessed Mar 17 2021.
- 311 2. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with
312 Severe Covid-19. N Engl J Med **2020**; 382:1787-99.
- 313 3. SolidarityTrialConsortium WHO, Pan H, Peto R, et al. Repurposed Antiviral Drugs for
314 Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med **2021**; 384:497-511.
- 315 4. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent
316 Severe Covid-19 in Older Adults. N Engl J Med **2021**; 384:610-8.

- 317 5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final
318 Report. N Engl J Med **2020**; 383:1813-26.
- 319 6. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19.
320 N Engl J Med **2021**; 384:693-704.
- 321 7. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent
322 Plasma in Covid-19 Severe Pneumonia. N Engl J Med **2021**; 384:619-29.
- 323 8. Jin Y, Lei C, Hu D, Dimitrov DS, Ying T. Human monoclonal antibodies as candidate
324 therapeutics against emerging viruses. Front Med **2017**; 11:462-70.
- 325 9. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in
326 Outpatients with Covid-19. N Engl J Med **2021**; 384:229-37.
- 327 10. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody
328 Cocktail, in Outpatients with Covid-19. N Engl J Med **2021**; 384:238-51.
- 329 11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
330 Covid-19 Vaccine. N Engl J Med **2020**; 383:2603-15.
- 331 12. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273
332 SARS-CoV-2 Vaccine. N Engl J Med **2021**; 384:403-16.
- 333 13. Liu H, Wei P, Zhang Q, et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding
334 to Bamlanivimab in vitro. bioRxiv [Preprint] February 16, 2021 [cited 2021 Apr 8]. Available
335 from: <https://doi.org/10.1101/2021.02.16.431305>
- 336 14. Wu K, Werner AP, Koch M, et al. Serum Neutralizing Activity Elicited by mRNA-1273
337 Vaccine. N Engl J Med 2021.
- 338 15. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2

339 infection. *Nature* 2020; 584:115-9.

340 16. Wang R, Zhang Q, Ge J, et al. SARS-CoV-2 variants resist antibody neutralization and
341 broaden host ACE2 usage. *bioRxiv* [Preprint] March 15, 2021 [cited 2021 Apr 8]. Available
342 from: <https://doi.org/10.1101/2021.03.09.434497>.

343 17. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and
344 B.1.1.7. *bioRxiv* [Preprint] January 26, 2021 [cited 2021 Apr 8]. Available from:
345 <https://doi.org/10.1101/2021.01.25.428137>.

346 18. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized
347 monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
348 *Antimicrob Agents Chemother* 2013; 57:6147-53.

349 19. Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and
350 Circulation Half-Life. *Front Immunol* 2019; 10:1296.

351 20. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veasler D. Structure, Function, and
352 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020; 181:281-92.e6.

353 21. Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor
354 mimicry. *Nature communications* 2021; 12:250.

355 22. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. *New England*
356 *Journal of Medicine* 2021; 0:null.

357 23. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19
358 Vaccine against the B.1.351 Variant. *New England Journal of Medicine* 2021; 0:null.

359 24. Moruf A. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of
360 Bamlanivimab. U.S. Food and Drug Administration, 2021:26.

361 25. Large clinical trial will test combination monoclonal antibody therapy for mild/moderate
 362 COVID-19. Available at:
 363 <https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-mono>
 364 [clonal-antibody-therapy-mild-moderate-covid-19](https://www.nih.gov/news-events/news-releases/large-clinical-trial-will-test-combination-mono-clonal-antibody-therapy-mild-moderate-covid-19). Accessed March 24 2021.
 365

Figure 1 Trial Profiles

Figure 2. Observed Mean ($\pm$ Standard Deviation) Serum Concentration - Time Profiles of BRII-196 and BRII-198 Following A Single Intravenous Infusion Administration to The Healthy Adult Subjects

Table 1 Participant Demographics and Baseline Characteristics

	BRII-196-001				BRII-198-001			
	750 mg (n=3)	1500 mg (n=6)	3000 mg (n=3)	Placebo (n=4)	750 mg (n=3)	1500 mg (n=7)	3000 mg (n=3)	Placebo (n=4)
Median age, years	22.0	32.5	34.0	33.5	30.0	33.0	30.0	37.5
Men	3 (100%)	4 (67%)	3 (100%)	3 (75%)	2 (67%)	7 (100%)	3 (100%)	3 (75%)
Women	0	2 (33%)	0	1 (25%)	1 (33%)	0	0	1 (25%)
Race								
Han, Chinese	3 (100%)	6 (100%)	2 (67%)	3 (75%)	3 (100%)	6 (86%)	3 (100%)	4 (100%)
Other, Chinese	0	0	1 (33%)	1 (25%)	0	1 (14%)	0	0
Median body-mass index, kg/m ²	22.80	21.15	21.60	22.90	23.70	21.00	22.30	23.10

Table 2 Summary of Adverse Events of BRII-196-001 Study

	BRII-196 750mg (n=3)	BRII-196 1500mg (n=6)	BRII-196 3000mg (n=3)	Placebo (n=4)
Participants with any TEAE	3 (100%)	5 (83%)	2 (67%)	4 (100%)
Participants with Grade 1 TEAE	3 (100%)	5 (83%)	2 (67%)	4 (100%)
Participants with Grade 2 TEAE	1 (33%)	3 (50%)	0	2 (50%)
Participants with Grade 3 or above TEAE	0	0	0	0
Participants with serious TEAE	0	0	0	0
Participants with infusion reaction TEAE	0	0	0	0
Participants with TEAEs related to study drug	1 (33%)	3 (50%)	0	0
Participants with any TEAE leading to discontinuation of study drug	0	0	0	0
Death	0	0	0	0
Number of participants with AEs by MedDRA SOC ^a				
Investigations	3 (100%)	4 (67%)	2 (67%)	4 (100%)
Infections and infestations	1 (33%)	0	0	2 (50%)

TEAE=treatment-emergent adverse event. SOC=system organ class.

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

^a Only SOC's experienced by ≥ 2 participant or with the maximum severity category $\geq$ Grade 2 are included.

Table 3 Summary of Adverse Events of BRII-198-001 Study

	BRII-198 750mg (n=3)	BRII-198 1500mg (n=6)	BRII-198 3000mg (n=3)	Placebo (n=4)
Participants with any TEAE	3 (100%)	5 (83%)	0	4 (100%)
Participants with Grade 1 TEAE	2 (67%)	5 (83%)	0	3 (75%)
Participants with Grade 2 TEAE	1 (33%)	0	0	1 (25%)
Participants with Grade 3 or above TEAE	0	2 ^a (33%)	0	1 ^b (25%)
Participants with serious TEAE	0	0	0	1 ^b (25%)
Participants with infusion reaction TEAE	0	0	0	0
Participants with TEAEs related to study drug	2 (67%)	1 (17%)	0	0
Participants with any TEAE leading to discontinuation of study drug	0	0	0	0
Death	0	0	0	0
Number of participants with AEs by SOC ^c				
Investigations	3 (100%)	4 (67%)	0	3 (75%)
Gastrointestinal disorders	1 (33%)	1 (17%)	0	0
Injury, poisoning and procedural complications	0	0	0	1 (25%)

TEAE=treatment-emergent adverse event. SOC=system organ class.

Participants who experienced the same AE on more than one occasion (based on the specific category) are counted once in each relevant category. Percentages are based on the number of participants in the treatment group.

^a 1 participant had an elevated blood creatine phosphokinase of Grade 4 after excessive exercise, and 1 participant had an increased blood triglycerides of Grade 3 on Day 181. Both events were not considered as related to the study drug by the investigators and normalized within 1-3 weeks.

^b 1 participant receiving placebo had a serious TEAE (bilateral traumatic foot fracture leading to hospitalization, which was also reported as a Grade 3 TEAE). The participant recovered after surgery.

^c Only SOC's experienced by ≥ 2 participant or with the maximum severity category $\geq$ Grade 2 are included.

Table 4 BR11-196 and BR11-198 Pharmacokinetic Parameters Following A Single Intravenous Infusion Administration to The Healthy Adult Participants

Antibody	Dose (mg)	Number of Subject	C _{max} (μg/mL)	T _{max} (hour)	t _{1/2} (day)	CL (mL/day)	V _{ss} (L)	AUC _{last} (day*μg/mL)	AUC _{inf} (day*μg/mL)
BR11-196	750	3	268 (19.9)	4.6	48.6 (4.56)	84.7 (10.5)	5.34 (0.500)	8240 (764)	8940 (1040)
	1500	6	584 (75.1)	5.4	46.0 (8.09)	72.4 (8.40)	4.50 (0.208)	19300 (2430)	20900 (2380)
	3000	3	1300 (91.7)	6.6	44.6 (6.75)	72.2 (4.11)	4.35 (0.289)	38900 (2510)	41700 (2300)
BR11-198	750	3	244 (35.5)	4.7	75.9 (8.97)	59.4 (5.54)	6.17 (0.760)	10400 (911)	12700 (1240)
	1500	6	509 (107)	5.4	72.2 (8.45)	57.4 (9.50)	5.76 (0.981)	20900 (2950)	26800 (4700)
	3000	3	1017 (149)	6.8	83.0 (37.6)	53.9 (8.90)	6.07 (2.20)	42800 (9680)	56600 (8900)

SD=standard deviation, C_{max}=observed maximum serum concentration, T_{max}=time to reach observed maximum serum concentration, t_{1/2}=terminal half-life, CL=systemic clearance, V_{ss}=volume of distribution at steady state, AUC_{last}=area under the concentration–time curve from time zero to the last measurable concentration, AUC_{inf}=area under the concentration–time curve from time zero to infinity. All parameters are reported in three significant figures except T_{max} that is reported with median values.